Ignite Creation Date:
2024-05-06 @ 7:09 PM
Last Modification Date:
2024-10-26 @ 3:01 PM
Study NCT ID:
NCT05918445
Status:
RECRUITING
Last Update Posted:
2023-06-27
First Post:
2023-05-30
Brief Title:
PM8002 in the Treatment of Patients With Advanced Solid Tumors
Sponsor:
Biotheus Inc
Organization:
Biotheus Inc
Study Overview
Official Title:
Phase IbIIa Safety and Efficacy of PM8002 a Bispecific Antibody Targeting PD-L1 and VEGF-A as a Monotherapy in Patients With Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is to characterize the safety tolerability pharmacokinetics PK immunogenicity pharmacodynamics PD and anti-tumor activity of PM8002 a PD-L1VEGF bispecific antibody as a single agent in adult subjects with advanced solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None